Zydus Lifesciences' Q2 FY 2026-27 Quarterly Results

Result Summary

• Zydus Lifesciences Ltd reported a 1.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 29.0%.
• Its expenses for the quarter were up by 0.1% QoQ and 50.9% YoY.
• The net profit decreased 6.3% QoQ and decreased 25.1% YoY.
• The earnings per share (EPS) of Zydus Lifesciences Ltd stood at 9.28 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Zydus Lifesciences Ltd, previously known as Cadila Healthcare Ltd, is a prominent player in the pharmaceutical industry. The company is predominantly focused on the development, manufacturing, and marketing of a wide range of healthcare products. This includes formulations, active pharmaceutical ingredients (APIs), and vaccines. Zydus is known for its robust portfolio in the generics and specialty pharmaceuticals sector. The company has been actively involved in research and development to introduce new biosimilars and novel therapeutics. While specific recent developments are not detailed here, Zydus has been involved in various strategic initiatives, including partnerships and acquisitions, to expand its market presence and enhance its product offerings.

Revenue

In the second quarter of fiscal year 2027 (Q2FY27), Zydus Lifesciences Ltd reported a total income of ₹8,039.50 crores. This represents a marginal decrease of 1.0% compared to the previous quarter (Q1FY27), where the total income was ₹8,123.10 crores. Year-over-year, there was a significant increase of 29.0% from Q2FY26, when the total income was ₹6,232.20 crores. This growth can be attributed to the company's enhanced focus on expanding its market reach and optimizing its product mix over the past year.

Profitability

The company's profitability for Q2FY27 showed a decline in comparison to both the previous quarter and the same quarter in the prior year. Profit Before Tax (PBT) was ₹1,234.20 crores, reflecting a quarter-over-quarter decrease of 5.5% from Q1FY27 and a year-over-year decline of 26.9% from Q2FY26. The Profit After Tax (PAT) for Q2FY27 stood at ₹927.70 crores, marking a 6.3% decrease from Q1FY27 and a 25.1% decline from Q2FY26. These variations indicate changes in the cost structure or revenue streams over these periods. The Earnings Per Share (EPS) also decreased slightly by 0.7% from the previous quarter and by 25.8% compared to the same quarter last year, standing at ₹9.28.

Operating Metrics

Total expenses incurred by Zydus Lifesciences Ltd in Q2FY27 amounted to ₹6,806.60 crores, reflecting a marginal increase of 0.1% from Q1FY27, which recorded total expenses of ₹6,798.30 crores. On a year-over-year basis, total expenses rose by 50.9% from Q2FY26, when expenses were ₹4,510.60 crores. The company's tax expenses decreased by 5.7% quarter-over-quarter and by 26.4% year-over-year, amounting to ₹334.00 crores in Q2FY27. These metrics provide insights into the company's operational efficiency and cost management practices over the analyzed periods.